Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omnadren
- Development stage
- Unknown
- Lead developer
- Jelfa
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Omnadren is a pharmaceutical drug consisting of a combination of testosterone esters, designed for long-acting androgen replacement therapy. It functions as a hormone, supplementing testosterone levels in individuals with testosterone deficiency. The drug exerts its effects by binding to and activating androgen receptors, thereby promoting anabolic metabolism and influencing various physiological processes, including bone mineral density, cardiovascular function, and secondary sexual characteristics. It has been used in conditions such as male hypogonadism and hypoandrogen-metabolic syndrome.
- Brand names
- Omnadren
02
Targets
PR (Progesterone receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on Omnadren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omnadren.